Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon Sep 26, 2023 9:36am
175 Views
Post# 35654232

RE:RE:RE:RE:RE:RE:RE:RE:RE:Financial Advisor

RE:RE:RE:RE:RE:RE:RE:RE:RE:Financial AdvisorTo put a statistical spin on thing.

The FDA approves things not based on the %CR but based on the statistics for that data presented.

If you think about a company with a drug that has a 40% respsonse in the first 10 patients treated. That 40% response translates into a true response that could be anywhere from 10-70%. Imagine you have a massive jar of jelly beans and  you pull 10 out randomly. Just because your small handful contains 4 green ones and 6 red ones doesn't mean that the massive jar is made up of 40% green ones. The FDA requires a big enough handful so that EVEN WHEN YOU CONSIDER the lower bound, the results are good. In the jelly bean example, 10% is the lower bound.

The FDA panel from way back indicated support for a drug that could achieve

- 40%-50% at 6 months (note that they don't list 3m CR or CR at any time)
- 30% for 18-24 months, with the lower bound of the 95% confidence interval excluding 20%

Using the most up to date patient numbers, my math says for 95% confidence interval we are at:
3m: 44-71% based on 57 treated and evaluable.
6m: 40-65% - (just meet this one on the lower bound) based on 53 treated and evaluable.
12m: 27-51% based on 42 treated and evaluable.
15m: 23-49% (meets the 20% on the lower bound) based on 39 treated and evaluable.

So Graham, while nothing is proven, one can say that true efficacy of Ruvidar for initial (3month) CR is somewhere between 44 and 71% and the true 15 m CR is between 23 and 49%.

Adstiladrin was approved on 24% CR with a study of 103 patients that had reached the 12m mark. The true value of of CR therefore may not have even reached 20% lower bound based on the number of patients. The 95% confidence interval is 14-34% for that CR.



<< Previous
Bullboard Posts
Next >>